"We are pleased to have [Jon] join us on our mission to save the lives and quality of life of stroke victims around the world." Clay Larsen, CEO of Vesselon
Norwalk, CT (PRWEB) March 11, 2015
Vesselon, Inc., a preclinical stage therapeutics company today announced that Jon Serbousek was named Chairman of the Board of Directors, effective February 9, 2015.
“Jon’s extensive experience in globally commercializing new medical technologies during his tenure at major medical device companies, such as Biomet, Medtronic and DePuy, will be extremely important to us as we progress. We are pleased to have him join us on our mission to save the lives and quality of life of stroke victims around the world,” stated Clayton Larsen, Co-Founder, President and CEO of Vesselon.
Mr. Serbousek is currently Worldwide President of Biomet Biologics and Sr. Vice President of Biomet, Inc., a worldwide innovator in the design and manufacture of products for the orthopedic, sports medicine, biologic, spine, cranio-maxillofacial and dental markets. Biomet Biologics, LLC is an internally ventured medical technology company, offering solutions to repair and regenerate damaged or degenerated hard and soft tissues. He has also held the positions of Group President of Orthopedics and President of US Orthopedics at Biomet.
Prior to Biomet, Jon held various general management positions with Medtronic, most recently as Worldwide Vice President and General Manager, Biologics for Medtronic’s Spinal and Biologics business. He also served in the role of Vice President and General Manager, Biologics, New Technology Development and Asia Pacific–Emerging Markets (APEC) while incubating disruptive Orthopedic and Interventional Spine start-up businesses. He had also served as Division President for a number of Medtronic business units and divisions. Before joining Medtronic, Serbousek served as Vice President of Marketing and Product Development for DePuy Orthopedics, a Johnson and Johnson company.
Mr. Serbousek earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland. Mr. Serbousek has held numerous board positions for profit and not-for-profit organizations and is currently active with OrthoWorx (Chairman), BioCrossroads, BioCrossroads Executive Committee, and Indiana BioSciences Research Institute Boards. Additionally, he is a member of the University of Memphis’ Herff School of Engineering Advisory Council and Grace College Campaign Steering Committee.
“Vesselon’s noninvasive prehospital approach and technology have the potential to significantly benefit the lives of those afflicted with acute onset stroke,” commented Mr. Serbousek. “I look forward to being a part of the team that makes this breakthrough treatment a commercial reality.”
Vesselon, Inc., a Spencer Trask venture, is a preclinical stage medical device company seeking to transform ischemic stroke treatment. We are developing a new immediate treatment platform that will use non-imaging ultrasound and a contrast agent of microbubbles to dissolve clots. Just as the introduction of the AED enabled first responders to save cardiac arrest victims’ lives, we believe our device could reduce treatment time from hours to minutes and have the potential to save the lives of and quality of life for ischemic stroke victims.
About Spencer Trask Ventures
For more than 20 years, Spencer Trask Ventures, Inc. has united investors and entrepreneurs to build valuable companies that better the world. Our clients have invested more than $1 billion in start-up companies that went on to make significant advances in healthcare, technology and life sciences.